RNA

+ Watchlist + Portfolio

Avidity Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.71
52-Week Range: $11.13 – $16.77
Market Cap: $230.58M
P/E (TTM): —
EPS (TTM): -5.44
Dividend Yield: —

Advanced Metrics

Price/Book: 0.98
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: -56.37%
Operating Margin: -752.93%
Profit Margin: -184.15%
Current Ratio: 8.73
Debt/Equity: 0.01
Total Debt: $1.68M
Free Cash Flow: —
Revenue Growth: -21.90%
Earnings Growth: —
Enterprise Value: $-27.70M

RNA Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$9.76M	$10.90M	$18.62M
Research & Development	$12.65M	$19.20M	$53.76M
Selling, General & Admin	$3.50M	$4.92M	$41.68M
Operating Expenses	$16.15M	$24.11M	$95.43M
Operating Income	-$6.39M	-$13.22M	-$76.81M
EBITDA	-$6.25M	-$13.05M	-$76.49M
Pretax Income	-$6.38M	-$13.22M	-$76.83M
Income Tax	$0.00	$11.91M	-$142.00K
Net Income	-$6.38M	-$25.12M	-$76.68M
Diluted EPS	-0.37	-1.47	-2.89
Diluted Shares	17.12M	17.12M	17.11M

RNA Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Cash & Equivalents	—	—	$270.00M
Receivables	$751.00K	$0.00	—
Current Assets	$856.00K	$483.00K	$272.85M
Total Assets	$10.29M	$7.19M	$278.35M
Current Liabilities	$33.80M	$26.80M	$41.80M
Total Debt	$9.85M	$6.80M	$3.67M
Total Liabilities	$80.91M	$68.29M	$71.07M
Shareholders' Equity	-$70.62M	-$61.11M	$207.29M
Working Capital	-$32.95M	-$26.32M	$231.04M

RNA Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	$56.39M	-$22.55M	-$41.13M
Capital Expenditure	-$320.00K	-$266.00K	-$1.45M
Free Cash Flow	$56.07M	-$22.82M	-$42.57M
Depreciation & Amortisation	$138.00K	$172.00K	$323.00K
Stock-Based Compensation	$2.51M	$3.18M	$7.68M
Investing Cash Flow	-$320.00K	-$266.00K	-$1.45M
Financing Cash Flow	-$56.07M	$22.82M	$42.57M

RNA Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Revenue	$2.97M	$1.57M	$859.00K	$19.64M
Research & Development	$21.45M	$6.94M	$18.50M	$16.66M
Selling, General & Admin	$25.78M	$2.09M	$30.40M	$20.26M
Operating Expenses	$47.22M	$9.03M	$48.89M	$36.91M
Operating Income	-$44.25M	-$7.45M	-$48.03M	-$17.28M
EBITDA	-$44.19M	-$7.40M	-$47.91M	-$17.13M
Pretax Income	-$44.24M	-$7.45M	-$48.03M	-$16.63M
Income Tax	$1.95M	—	$34.00K	—
Net Income	-$46.20M	-$7.45M	-$48.07M	-$16.63M
Diluted EPS	—	-0.44	—	-0.97
Diluted Shares	—	17.12M	—	17.11M

RNA Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Cash & Equivalents	—	$270.00M	$270.00M	$267.85M
Receivables	$0.00	—	—	$15.00M
Current Assets	$483.00K	$271.26M	$272.85M	$285.56M
Total Assets	$7.19M	$277.54M	$278.35M	$292.36M
Current Liabilities	$26.80M	$31.74M	$41.80M	$21.91M
Total Debt	$6.80M	$4.28M	$3.67M	$2.68M
Total Liabilities	$68.29M	$64.69M	$71.07M	$58.26M
Retained Earnings	—	—	—	$12.13M
Shareholders' Equity	-$61.11M	$212.85M	$207.29M	$234.10M
Working Capital	-$26.32M	$239.52M	$231.04M	$263.66M

RNA Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.26M	-$11.10M	-$19.25M	-$31.14M
Capital Expenditure	-$218.00K	—	-$879.00K	-$2.10M
Free Cash Flow	-$8.48M	-$11.10M	-$20.13M	-$33.24M
Depreciation & Amortisation	$58.00K	$53.00K	$122.00K	$151.00K
Stock-Based Compensation	$1.09M	$1.21M	$3.55M	$12.21M
Investing Cash Flow	-$218.00K	$0.00	-$879.00K	-$2.10M
Financing Cash Flow	$8.48M	$11.10M	$20.13M	$301.50M
Net Change in Cash	—	—	—	$268.26M

Market Snapshot

About

Avidity Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company combines the targeting ability of monoclonal antibodies with the precision of oligonucleotide therapies to address genetic diseases affecting muscle and other tissues. Avidity is advancing multiple programs for rare genetic diseases.